Phase Forward-Medpace Relationship Proves Successful

New Clinical Trial Customers Punctuate Success of Phase Forward-Medpace Relationship
Medpace Leverages Phase Forward’s InForm Solution and CRO Partnership Program to Win New Business

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that Medpace, one of its contract research organization (CRO) partners, has been awarded several large clinical trials using Phase Forward’s award-winning InForm electronic data capture (EDC) solution. The majority of these trials were awarded in 2008 and have spanned Phases I through III, with focuses in the cardiovascular, metabolism and oncology therapeutic areas.
 
A Phase Forward customer since 2006, Cincinnati-based Medpace is a rapidly growing CRO, with more than 800 employees and operations in 40 different countries. After using the InForm tool for a number of years, Medpace committed to an enterprise agreement in 2007 to bring the software in-house. Medpace subsequently has been able to leverage its expertise with InForm to win both new and repeat business across multiple market segments, including both large and small pharmaceutical accounts.
 
“To date, our experience with InForm has served us extremely well,” said Catherine Soldano, executive director of business development and marketing at Medpace. “From the start, we liked how intuitive the software is at helping us more efficiently manage site data, particularly for larger trials. By bringing this technology in-house, we were able to rapidly ramp up and outpace the EDC adoption rate of some of our larger competitors who have been slower to embrace its benefits.”
 
“Medpace’s success is exactly the type of result we planned for when we developed our CRO partnership program,” said Mike Davies, vice president, global CRO partnerships at Phase Forward. “We enable our CRO partners with the right technology solutions and assist them commercially through joint marketing and sales campaigns. We look forward to continued success with Medpace.”
 
Phase Forward’s CRO partnership strategy is designed to assist CRO clients achieve success in both the short and long term. Its customized structure and flexible pricing options help CROs of all sizes to invest in their own capabilities and capitalize on new growth opportunities. Across all of its solutions, Phase Forward has over 90 CRO customers as of the end of 2008.
 
About Medpace, Inc.
Medpace is a leading global full-service clinical research organization led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, oncology, and nephrology. Medpace has assembled the industry’s most experienced and therapeutically focused team to execute at every level of the company’s operations, providing complete and seamless drug development services.
 
Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.
 
Medpace provides centralized image management and reading from Imagepace, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and Phase I / IIa research services from Medpace Clinical Pharmacology. www.medpace.com